Sauce Essentials Announces U.S. Northeast Expansion Plans for 2025
Premium Cannabis Brand Set to Launch in New York, New Jersey and Maryland
COSTA MESA, CA - April 21, 2025 ( NEWMEDIAWIRE ) - Sauce Essentials ('Sauce' or 'the Company'), one of the fastest growing US premium cannabis brands committed to providing top-quality products at affordable prices, announced today the Company's expansion plans into three new Northeastern states. Later this year, consumers in New York, New Jersey and Maryland will have access to Sauce Essentials' premium cannabis vape lines – including Sauce Live Resin AIO Vape Bars & AIO Vape Classics – at various retailers in each new state.
The Company's entry into these markets marks a significant milestone in its mission to provide top-tier cannabis products nationwide. With a focus on delivering consistency, flavor, and consumer experiences, Sauce is committed to rigorous testing and product safety, ensuring all products exceed state compliance standards in every market they operate in, establishing themselves as a trusted name among consumers and retailers alike. Through partnerships with trusted third-party labs, the Company prioritizes transparency and consumer confidence.
'We're thrilled to bring Sauce to these new and vibrant cannabis markets in the Northeast,' said Dylan Spencer, Chief Marketing Officer at Sauce Essentials. 'Our mission has always been to offer accessible, premium cannabis products at affordable prices for consumers while upholding the highest standards of product quality and safety. This expansion is a huge step forward for us in bringing trusted cannabis experiences to even more consumers.'
Beyond providing premium products, Sauce's expansion will create local jobs and partnerships, supporting the growth of the cannabis industry in each market. To stay up to date with Sauce's market launch dates and product availability, visit www.sauceessentials.com.
About Sauce Essentials
In 2018, Sauce Essentials set out on a mission to create exceptional cannabis products that consumers can trust, and provide them with a welcoming culture and quality experience, no matter their vibe.
With a spirit of innovation, brand consistency, and high standards, Sauce introduced Sauce Essentials to the recreational market in 2021, setting the standard for premium cannabis products in the US. Sauce broadened their product offerings by introducing their Dream Pen CBN Vapes, Bursts High Potency Gummies, and Classics Vapes to the cannabis market, showcasing their commitment to the quality of hardware, materials, and ingredients while ensuring the lowest defect rate among their known competitors.
Sauce Essentials excels in scalability and customer retention, continuously innovating to disrupt multiple categories and elevate the brand. Present in eight states and expanding, Sauce delivers exceptional value without compromising on quality, supported by sustainability programs that reduce waste and promote responsible cultivation practices.
For more information about Sauce Essentials and where to find products in your local area, visit www.sauceessentials.com. Follow Sauce Essentials on Instagram @sauceesentials.
Public Relations Contact
Americana Communications
[email protected]
www.americanapr.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
CopAur Minerals Announces $85,000 Non-Brokered Private Placement Increasing Previously Closed Financing $505,500 Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - CopAur Minerals Inc. (TSXV: CPAU) (the "Company") is pleased to announce that it has arranged a non-brokered private placement financing for gross proceeds of $85,000 (the "Private Placement") increase to the $505,500 previously closed financing to $590,500. The Private Placement will consist of 850,000 units at a price of $0.10 per unit. Each unit will comprise one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share at a price of $0.15 for a period of 18 months from the date of issuance. The warrants will be subject to an acceleration clause: if the Company's common shares trade at or above $0.20 for 10 consecutive trading days on the TSX Venture Exchange, the Company may accelerate the expiry date of the warrants to 30 days following the date on which notice is provided to the holders. Jeremy Yaseniuk, the CEO and a director of the Company, intends to subscribe for 350,000 Units under the Private Placement. The issuance of securities to a director and officer pursuant to the Private Placement is considered to be a "related party transaction" subject to the requirements of TSXV Policy 5.9 and Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). As a result of the proposed purchase of these Units by Mr. Yaseniuk, the requirements under MI 61-101 for a formal valuation and minority shareholder approval are engaged. The Company intends to rely on exemptions from the formal valuation and minority shareholder approval requirements available under sections 5.5(a) and 5.7(1)(a) of MI 61-101 on the basis that amount invested in the Private Placement by the related party will not exceed 25% of the Company's market capitalization. Proceeds from the Private Placement will be used to advance the Company's exploration initiatives and for general working capital purposes. Closing of the Private Placement is subject to regulatory approval, including that of the TSX Venture Exchange. All securities issued will be subject to a four-month hold period in accordance with applicable securities laws. On another matter, the issuance of 3,000,000 stock options at $0.15 as previously announced May 8, 2025 have been cancelled. About CopAur CopAur is an exploration company focused on developing projects within the emerging, mineral-rich mining regions of Nevada. The Company is backed by a dynamic and experienced team of resource professionals advancing its projects in Nevada with the flagship project being Kinsley Mountain Gold Project, a Carlin-style project located 90 kilometres south of the Long Canyon mine (currently in production under the Newmont/Barrick joint venture, Nevada Gold Mines). ON BEHALF OF THE BOARD OF COPAUR MINERALS Yaseniuk, Chief Executive Officer For more information, please contact: Jeremy Yaseniuk, Chief Executive Officer & DirectorTel: +1 (604) 773-1467Email: jeremyy@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward-Looking Information This news release contains forward-looking statements. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revised any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Solis Minerals Seeks Delisting from TSXV
HIGHLIGHTS Solis Minerals has sought a delisting from the TSXV with the ASX to become the primary exchange. TSXV shareholders, on the Canadian share register, may convert their shares into CDIs held in Australia and trade the CDIs on the ASX. TSXV shareholders reflect approximately eight per cent of the Company's securities following Solis Minerals' placement in February 20251. A single, primary listing on the ASX, with a proposed re-domiciliation of the Company to Australia, will reduce corporate costs and governance considerations to better focus resources on exploration. West Leederville, Western Australia--(Newsfile Corp. - June 9, 2025) - Solis Minerals Limited (ASX: SLM) (TSXV: SLMN) ("Solis Minerals" or the "Company") announces that it has applied to the TSX Venture Exchange ("TSXV") to voluntarily delist the common shares of the Company (the "Delisting"). Solis Minerals believes that the Company's shares and overall liquidity will benefit from a centralised focus on the Australian Securities Exchange ("ASX"). Additionally, cost and governance efficiencies will be realised through one primary listing. Instructions regarding the process of converting common shares (the "Shares") into "CHESS Depositary Interests" ("CDIs"), enabling them to be traded on the ASX, may be found below. The Delisting is subject to final approval by the TSXV. The Company expects the Delisting to occur on or around June 23, 2025 (the "Delisting Date"). The Company also announces that, in connection with the Delisting, it expects to proceed with a re-domiciliation of the Company to Australia (the "Re-Domiciliation"). The Re-Domiciliation will be subject to the approval of the Company's shareholders and applicable regulatory approvals. Further details regarding the Re-Domiciliation will be made in a subsequent press release. Chief Executive Officer, Mitch Thomas commented: "We believe that streamlining our listing structure is in the best interests of all shareholders, as it will enhance ASX share liquidity and lower administrative costs associated with maintaining a dual-listing structure between Australia and Canada. We welcome existing TSXV shareholders to convert their shares to CDIs. Instructions on how to do so are included on the following page. This change will release more resources to focus on exploration of our highly attractive copper-gold projects in southern Peru. The commencement of drilling last week at Chancho al Palo - with Ilo Este to follow shortly - marks the start of a very exciting period of news flow for shareholders." Instructions for Canadian shareholders to Convert their Shares into CDIs If a shareholder wishes to trade on the ASX, they will need to request to convert, on a 1:1 basis, their unrestricted Shares held on the Canadian share register into CDIs held in Australia. This can be done in one of the following ways: If the Shares are held by the shareholder directly on the Canadian share register in (a) book entry form in the Direct Registration System, or (b) in certificated form, then the shareholder will need to complete and submit a CDI Issuance (Canadian Register to Australian CDI Register) form (the "CDI Issuance Form") to Computershare's Global Transaction Team in Canada ("GT Canada") accompanied by share certificates (if applicable), to the following address:Post: Computershare Investor Services Global Transaction Team100 University Ave, 8th FloorToronto, Ontario, M5J 2Y1 CanadaEmail: CDI Issuance Form can be downloaded from select 'Printable Forms'; select 'Global Transaction Forms'; and choose 'Register Removal Request - Canada to Australia CDIs' For Shares held through the Canadian Depository for Securities ("CDS") with a broker or other intermediary (a "CDS Participant"), the CDS Participant will need to initiate a CDS Stock Withdrawal for the number of Shares to be converted into CDIs. At the same time, the CDS Participant will complete and submit a CA/AU xSettle instruction (or CDI Issuance Form) to GT Canada, with this matched to the withdrawal of the Shares. xSettle is Computershare's secure online cross-border instruction portal used by market participants. Once a valid request is provided to GT Canada, the CDIs will generally be issued in Australia within 1-2 business days (time zones permitting). No CDI issuance fee will be charged to an individual holder for converting Shares into CDIs, however, a cross-border transaction fee may be charged to the holder by any intermediaries (i.e. brokers or custodians) which are involved. For inquiries on the Share to CDI conversion process, shareholders can contact GT Canada: Phone: +1 877 624 5999 Email: . ENDS This announcement has been authorised for release by the Board. ContactMitch ThomasChief Executive OfficerSolis Minerals Limitedmthomas@ 458 890 355 Media & Broker Enquiries:Fiona Marshall & Jason MackWhite Noise Communicationsfiona@ 400 643 799 Neither the TSX Venture Exchange nor its Regulation Service Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this news release. About Solis Minerals Limited Solis Minerals is an emerging exploration company, focused on unlocking the potential of its South American copper portfolio. The Company is building a significant copper portfolio around its core tenements of Ilo Este and Ilo Norte and elsewhere in the Southern Coastal Belt of Peru and currently holds 81 concessions totalling 69,200 Ha. The Company is led by a highly-credentialled and proven team with excellent experience across the mining lifecycle in South America. Solis Minerals is actively considering a range of copper opportunities. South America is a key player in the global export market for copper and Solis Minerals, under its leadership team, is strategically positioned to capitalise on growth opportunities within this mineral-rich region. Forward-Looking Statements This news release contains certain forward-looking statements that relate to future events or performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, but not limited to, the risk that the Delisting does not proceed in the manner contemplated or at all, the risk the Re-Domiciliation does not occur, market conditions, availability of financing, actual results of the Company's exploration and other activities, environmental risks, future metal prices, operating risks, accidents, labour issues, delays in obtaining governmental approvals and permits, and other risks in the mining industry. All the forward-looking statements made in this news release are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR+ at These forward-looking statements are made as of the date hereof, and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required by applicable law. 1 Refer to ASX:SLM Announcement 26 February 2025: "$4.5M Placement Bolsters Funding ahead of Drilling in Peru" To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Devonian Appoints New Officers and Announces Grant of Stock Options
QUÉBEC CITY, June 09, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Dr. André Boulet as Chief Executive Officer of the Corporation, replacing Mr. Luc Gregoire who will continue in the new role of Executive Vice-President Strategy of the Corporation, effective June 9, 2025. "As we enter a new phase of development, we are fortunate to retain Luc's deep strategic insight and leadership in a role focused on long-term planning and innovation. As Executive Vice President of Strategy, he will continue to drive key initiatives, ensuring continuity and alignment with our mission while supporting the executive team through this important transition," stated Dr. Boulet, President & CEO of the Company. "I look forward to continuing to advise the executive team and help garner support from external stakeholders, as the Company sharpens its focus on its high potential anti-inflammatory clinical programs," said Luc Gregoire. The Corporation also announced that its board of directors has approved the grant of options to purchase common shares of the Corporation (the "Stock Options") primarily for a director of the Corporation and the Chief Financial Officer, both of whom joined the organization in the past few months. The Stock Options were granted at an exercise price of $0.15 for a period of 10 years from the date of grant, which ends on June 9, 2035. An aggregate of 438,596 Stock Options was granted to a director of the Corporation and an aggregate of 850,000 Stock Options was granted to employees of the Corporation. 50.33% of these Stock Options are exercisable immediately, 12.42 % shall vest upon the date that is 12 months from the date of issuance; 12.42 % shall vest upon the date that is 24 months from the date of issuance 12.42 % shall vest upon the date that is 36 months from the date of issuance and the remaining 12.42 % shall vest upon the date that is 48 months from the date of issuance. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the appointment of Ms. Krasteva as Chief Financial Officer and, generally, the above "About Devonian" paragraph, which essentially describes the Corporation's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. View source version on Contacts Devonian Health Group Inc. Dr. André BouletChief Executive OfficerTelephone: 1 (514) 248-7509E-mail: investors@ Sign in to access your portfolio
